Search for drugs:
Typing the drug name to query
DALBAVANCIN
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology: In a randomized, positive- and placebo-controlled, thorough QT/QTc study, 200 healthy subjects received dalbavancin 1000 mg IV, dalbavancin 1500 mg IV, oral moxifloxacin 400 mg, or placebo. Neither dalbavancin 1000 mg nor dalbavancin 1500 mg had any clinically relevant adverse effect on cardiac repolarization.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
0
24092
Other ADRs
0
38381587
Odds Ratio = N/A
Drug Property Information
ATC Code(s):
- J01XA04 - dalbavancin
- J01XA0 -
- J01XA - Glycopeptide antibacterials
- J01X - OTHER ANTIBACTERIALS
- J01 - ANTIBACTERIALS FOR SYSTEMIC USE
- J - ANTIINFECTIVES FOR SYSTEMIC USE
Active Ingredient:DALBAVANCIN HYDROCHLORIDE
Active Ingredient UNII:33WDQ7T81E
Drugbank ID:DB06219
PubChem Compound:23724878
CTD ID: C469289
CAS Number:171500-79-1
Dosage Form(s):injection, powder, for solution
Route(s) Of Administrator:intravenous
Daily Dose:
- 1500.0 mg/day J01XA04
Chemical Structure: 
SMILE Code:
Reference
1: A thorough QT study with dalbavancin: a novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin-structure infections.
[Dunne Michael W,Zhou Meijian,Darpo Borje]Int J Antimicrob Agents,2015 Apr;45(4):393-8. PMID: 25681068
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.